创新药行业再迎政策支持，医疗创新ETF(516820)连续8天净流入

Group 1 - The China Securities Pharmaceutical and Medical Device Innovation Index (931484) decreased by 0.45% as of January 28, 2026, with mixed performance among constituent stocks, led by Pien Tze Huang with a 1.57% increase [1] - The Medical Innovation ETF (516820) has seen continuous net inflows over the past 8 days, with a maximum single-day net inflow of 41.8265 million yuan, totaling 156 million yuan, averaging 19.475 million yuan per day [1] - The newly revised Implementation Regulations of the Drug Administration Law of the People's Republic of China were officially released on January 27, marking the first comprehensive revision in 23 years, aimed at enhancing the drug regulatory system and supporting high-quality development of the pharmaceutical industry [1] Group 2 - The Medical Innovation ETF closely tracks the China Securities Pharmaceutical and Medical Device Innovation Index, which selects 30 profitable and growth-oriented listed companies in the pharmaceutical and medical device sectors [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, Mindray, Aier Eye Hospital, Pien Tze Huang, New Horizon, East China Pharmaceutical, CRISPR Therapeutics, Ailisi, and Gan Li Pharmaceutical, collectively accounting for 63.75% of the index [2] Group 3 - The current adjustment in the pharmaceutical sector does not change the logic of innovative drugs and devices, maintaining a "neutral" rating for the industry [1] - Aidi Kang Holdings, a pioneer in the independent medical laboratory (ICL) industry in China, acquired 100% of the shares of Crown Bio, a global CRO focused on oncology and immuno-oncology, for 204 million USD in November 2025, enhancing its testing service capabilities in core disease areas [1]